mardi 2 juin 2020

Onco Actu du 2 juin 2020


1. BIOLOGIE



Cancer cells cause inflammation to protect themselves from viruses [Francis Crick Institute]











Resistance to immunosurveillance favors cluster cancer metastasis [Baylor College of Medicine]











Tumor Microbiome Appears to Vary With Cancer Type [Genome Web]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



ACMG Offers Guidance on Incorporating Genomic Data into Electronic Health Records [Genome Web]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Mini tumours help predict how cancer handles the heat of innovative cancer treatments [Institute of Cancer Research]











5.10 TRAITEMENTS - ESSAIS



More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease [NCI]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



A boost for cancer immunotherapy [MIT]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



WuXi AppTec welcomes vet of Celgene's troubled cell therapy program to CAR-T leadership role [Fierce Pharma]











5.12.6 IMMUNOTHÉRAPIES - AMM



FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [FDA]










Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug [EndPoints]











Roche's Tecentriq gets a green light to challenge Bayer with first-in-class liver cancer nod [Fierce Pharma]











5.2 PHARMA



Pfizer's Ibrance misses shot at big new market with early breast cancer failure [Fierce Pharma]










Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer [Pfizer]











In a stinging setback, Pfizer’s cancer blockbuster Ibrance flops in key adjuvant setting [EndPoints]











5.2.1 PHARMA - PARTENARIATS



AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors [AbbVie]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod [Fierce Pharma]











FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC [FDA]










Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer [AstraZeneca]











AstraZeneca-Merck Lynparza gets EMA's positive recommendation [Reuters]











Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation [Novartis]











CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer [Roche]











Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer [Lilly]











XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis [Astellas]











Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020 [EMA]











5.5.3 ASCO (PROSTATE)



ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer [Institute of Cancer Research]











5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)



With new Allogene data, same promise, questions surround 'off the shelf' CAR-T [Biopharma Dive]










6. LUTTE CONTRE LES CANCERS



Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer [STAT]











6.1 OBSERVATION



Assessing cancer diagnosis in children with birth defects [Baylor College of Medicine]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Over 2 million people in backlog for cancer care [Cancer Research UK]










Millions in UK miss cancer screenings, tests and treatments due to Covid-19 [The Guardian]











6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES



Nature retracts study touted as step toward treatments for bone diseases [Retraction Watch]











6.7 DMP, BIG DATA & APPLIS



New CancerLinQ Discovery® Research Platform Offers Researchers Easy Access to Real-World Cancer Data [ASCO]